Back to top

Buy Rating Reaffirmed on Robust HARMONi Data and BLA Progress; $40 Price Target Maintained

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Summit Therapeutics, retaining the price target of $40.00. Yigal Nochomovitz has given...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Summit Therapeutics PLC (SMMT)